Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa

Perez, Leandro Reus Rodrigues; Barth, Afonso Luís

doi:10.1016/S1413-8670(11)70196-9

Article information

Abstract

Biofilm production is an important mechanism for bacterial survival and its occurrence together with antimicrobial resistance represents a challenge for clinical management. Here, we evaluated the ability for biofilm production among P. aeruginosa isolates from patients with or without cystic fibrosis (CF) using two distinct media, besides determining the antimicrobial susceptibility profile of these isolates for eight antimicrobial agents. The ability for biofilm production when TSB medium was used was higher than when used CF sputum media (p=0.0198). However, P. aeruginosa isolates from CF have demonstrated similar performance for biofilm production, independently of the medium used. Besides, among the biofilm-producing isolates, those recovered from CF were more resistant to the carbapenems (meropenem and imipenem) agents than those isolates from non-CF isolates.

Keywords:

biofilm

Pseudomonas aeruginosa

cystic fibrosis

antimicrobial resistance

Full text is only available in PDF

References

[1.]

J. Emerson, M. Rosenfeld, S. McNamara, B. Ramsey, R.L. Gibson.

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Pediatr Pulmonol, 34 (2002), pp. 91-100

http://dx.doi.org/10.1002/ppul.10127 | Medline

[2.]

M.R. Kosorok, L. Zeng, S.E. West, et al.

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.

Pediatr Pulmonol, 32 (2001), pp. 277-287

Medline

[3.]

D.D. Sriramulu, H. Lünsdorf, J.S. Lam, U. Römling.

Microcolony formation: a novel model of Pseudomonas aeruginosa for the cystic fibrosis lung.

J Med Microbiol, 54 (2005), pp. 667-676

http://dx.doi.org/10.1099/jmm.0.45969-0 | Medline

[4.]

A.J. Jesaitis, M.J. Franklin, D. Berglund, et al.

Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions.

J Immunol, 171 (2003), pp. 4329-4339

Medline

[5.]

R. Singh, D. Paul, R.K. Jain.

Biofilms: implication in bioremediation.

Trends Microbiol, 14 (2006), pp. 389-397

http://dx.doi.org/10.1016/j.tim.2006.07.001 | Medline

[6.]

D. Worlitzsch, R. Tarran, M. Ulrich, et al.

Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

J Clin Invest, 109 (2002), pp. 317-325

http://dx.doi.org/10.1172/JCI13870 | Medline

[7.]

G.A. O’Toole, L.A. Pratt, P.I. Watnick, D.K. Newman, V.B. Weaver, R. Kolter.

Genetic approaches to study biofilms.

Methods Enzymol, 310 (1999), pp. 91-109

Medline

[8.]

S. Stepanovic, D. Vucovic, V. Hola, et al.

Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci.

APMIS, 115 (2007), pp. 891-899

http://dx.doi.org/10.1111/j.1600-0463.2007.apm_630.x | Medline

[9.]

Clinical and Laboratory Standards Institute - CLSI. Performance standards for antimicrobial susceptibility testing. 19th informational supplement M100-S19. Wayne, PA: CLSI/(NCCLS), 2009.

[10.]

J.W. Costerton, P.S. Stewart, E.P. Greenberg.

Bacterial biofilms: a common cause of persistent infections.

Science, 284 (1999), pp. 1318-1322

Medline

[11.]

B. Frederiksen, S. Lanng, C. Koch, N. Hoiby.

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

Pediatr Pulmonol, 21 (1996), pp. 153-158

http://dx.doi.org/10.1002/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R | Medline

[12.]

F. Delissalde, C.F. Amábile-Cuevas.